How Is Drug-Resistant Epilepsy Diagnosed?

Drug-resistant epilepsy is defined as the failure of two appropriately chosen, adequately dosed antiepileptic drugs to achieve sustained seizure freedom. Once that threshold is reached, the probability of a third drug succeeding drops to under five percent. Before applying the label, two things must be ruled out: an incorrect diagnosis, and avoidable causes of drug failure such as wrong drug selection, subtherapeutic dosing, or poor adherence. Both are common enough to change management in a meaningful proportion of referrals.

According to Dr. Gurneet Singh Sawhney, a leading neurosurgeon in Mumbai, “The single most important step in a drug-resistant epilepsy workup is confirming the diagnosis a significant number of patients referred for refractory epilepsy don’t have epilepsy at all, they have non-epileptic attack disorder or a misclassified seizure type.”

What Confirms the Drug-Resistant Epilepsy Diagnosis?

Confirmation requires verifying the epilepsy diagnosis itself and ruling out modifiable causes of treatment failure not just counting failed drugs.

• Video-EEG monitoring: Prolonged inpatient recording confirms whether episodes are epileptic, identifies seizure type correctly, and localises onset changing management in a substantial proportion of patients previously labelled drug-resistant without formal monitoring.
• Drug trial audit: Each medication trial is reviewed for correct drug selection, adequate dosing, and sufficient duration. Apparent resistance caused by choosing the wrong drug for the seizure type is not pharmacological resistance and can be corrected without further escalation.
• Epilepsy MRI protocol: Standard MRI frequently misses cortical dysplasia, hippocampal sclerosis, and small tumours. A dedicated epilepsy-protocol MRI at 3 Tesla with thin-cut coronal sequences is required. A negative epilepsy MRI is a different result from a negative routine MRI.
• Syndrome classification: Accurate classification determines which drug combinations are rational, which haven’t been adequately tried, and whether the syndrome carries an inherently poor medication response that pushes toward non-pharmacological treatment earlier.

Confirming drug resistance is a process that benefits from specialist epilepsy centre involvement rather than repeated medication changes in a general neurology setting the same centre that guides the full seizure treatment pathway from diagnosis through to surgical candidacy assessment.

What Investigations Complete the Drug-Resistant Epilepsy Workup?

Once drug resistance is confirmed, the workup shifts toward identifying whether a surgical or device-based option exists.

• Neuropsychological testing: Establishes cognitive baseline, identifies existing impairment, and guides surgical planning particularly critical in temporal lobe cases where memory lateralisation determines safe resection limits.
• PET and SPECT imaging: FDG-PET identifies hypometabolic zones between seizures; ictal SPECT localises onset during a seizure. Both are most valuable when MRI is negative and video-EEG localisation is incomplete.
• Intracranial EEG: When non-invasive workup cannot localise the seizure focus with sufficient confidence, stereo-EEG or subdural grid electrodes are implanted under functional neurosurgery guidance to record directly from regions of interest determining surgical eligibility, not just providing more data.
• Genetic testing: In children and adults with a family history or specific EEG patterns, genetic panel testing identifies mutations that alter drug selection directly some genetic epilepsies are worsened by commonly used antiepileptic drugs such as sodium channel blockers.

The workup ends when the team can answer whether resection, palliative disconnection such as corpus callosotomy, neuromodulation, or continued medical management is the best option for that patient’s specific seizure type, focus, and functional anatomy.

Why Choose Dr. Gurneet Singh Sawhney?

Dr. Gurneet Singh Sawhney holds MBBS, MS (General Surgery), and MCh (Neurosurgery), ranking first in the MCh university examination with a dedicated epilepsy surgery fellowship under Prof. Sugano at Juntendo University, Japan, and a functional neurosurgery fellowship under Prof. Taira at Tokyo Women’s Medical University, covering the complete drug-resistant epilepsy diagnostic pathway including video-EEG, epilepsy-protocol MRI, neuropsychological testing, PET, SPECT, and intracranial EEG.

His drug-resistant epilepsy assessments don’t begin with a surgical conversation they begin with confirming the diagnosis is correct, because the workup that follows a misdiagnosis wastes time and exposes patients to risks they shouldn’t carry.

Reference:

1. NIH: Drug-Resistant Epilepsy Diagnosis and Management
2. PubMed: ILAE definition of drug-resistant epilepsy

Disclaimer: The information shared in this content is for educational purposes only and not for promotional use.